SCHEMBL6708148

SCHEMBL6708148

N#CCc1ccc(OB(O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.42
KMT2A Q03164 2/20 0.41
PKM P14618 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 1/20 0.37
MMP3 P08254 2/20 0.34
NPC1 O15118 2/20 0.33
THRB P10828 1/20 0.33
RAB9A P51151 1/20 0.33
FLT3 P36888 1/20 0.33
PTPRC P08575 1/20 0.33
PTPN1 P18031 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TNF P01375 1/20 0.31
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28807848 0.78 ENPP2 (0.57) ENPP2KMT2AMMP3NPC1PTPRC
SCHEMBL11532120 0.76 L3MBTL1 (0.49) KMT2APKML3MBTL1GAAFLT3
SCHEMBL28229775 0.76 SYK (0.37) L3MBTL1GAAMMP3MAPTKDM4E
SCHEMBL3800806 0.75 CA1 (0.38) ENPP2KMT2A
SCHEMBL2154504 0.75 KMT2A (0.47) ENPP2KMT2APKML3MBTL1GAA
SCHEMBL1251529 0.74 LTA4H (0.50) ENPP2KMT2AMMP3
SCHEMBL3591237 0.72 ST14 (0.50) MAOB
SCHEMBL2202099 0.72 ENPP2 (0.52) ENPP2KMT2APKMMMP3RAB9A
SCHEMBL17215124 0.72 GAA (0.43) KMT2APKML3MBTL1GAAMMP3
SCHEMBL13203140 0.72 PKM (0.41) ENPP2KMT2APKML3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117412973-A Nitrogen-containing fused heteroaromatic bicyclic compounds as USP1 inhibitors and uses thereof 上海瑛派药业有限公司 2024-01-16 CN disclosed
CN-102917590-A Trycyclic compounds and pbk inhibitors containing the same ONCOTHERAPY SCIENCE INC 2013-02-06 CN disclosed
CN-1277823-C New benzothiazine and benzothiadiazine compounds,its preparation process and pharmaceutical composition containing said compounds SERVIER LAB (FR) 2006-10-04 CN disclosed
CN-1572791-A New benzothiazine and benzothiadiazine compounds,its preparation process and pharmaceutical composition containing said compounds SERVIER LAB (FR) 2005-02-02 CN disclosed
US-20040242572-A1 New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242572-A1 New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture MCHR2, MCHR1, NPY1R ENPP2 487/4885KMT2A 406/4885PKM 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.